Navigation Links
Bone Density Recovers After Teens Stop Injected Contraceptive

Lower bone density appears to recover in adolescent females once they stop using the injected contraceptive depot medroxyprogesterone acetate (DMPA), according to a study funded by the National Institute of Child Health and Human Development of the National Institutes of Health.

Previous studies had shown that women who use DMPA, marketed under the brand name Depo-Provera, experience a loss of bone mineral density during the time they are using the contraceptive. Because women are developing a large amount of their bone mass from ages 15 to 19, researchers were concerned that DMPA use might place adolescents at higher risk for bone fracture or osteoporosis later in life.

“This study shows that after adolescents stop using DMPA, their bone density can increase to levels comparable to those of other women in their age group,?said Duane Alexander, M.D., Director of the NICHD.

The study authors wrote that 10 percent of U.S. female adolescents from 15 to 19 who are using birth control use DMPA, as compared to 3 percent of U.S. women overall.

Researchers believe that DMPA interferes with bone mineral density by lowering levels of estrogen, a hormone that promotes bone mineral density in women.

The findings appear in the February Archives of Pediatrics and Adolescent Medicine. The study was conducted by Delia Scholes, Ph.D., of the Group Health Cooperative in Seattle, Washington, and her colleagues.

To conduct the study, the researchers measured hip, spine, and whole body bone mineral densities in 170 healthy female adolescents ages 14 to 18. Of these, 80 had used DMPA, and 90 had not. Some of the 90 who had not used DMPA had used other forms of contraception, including oral contraceptives. Oral contraceptives also contain hormones. Some contain a combination of the hormones estrogen and progestin, some contain only progestin. It is not known whether oral contraceptive use affects bone mineral density and NICHD is currently su
'"/>

Source:NIH


Page: 1 2 3

Related biology news :

1. Youth With HIV Take More Risks After New Meds Introduced
2. After a time-shift, mixed signals from the circadian clock
3. Drug Offers Alternative to Surgical Treatment After Miscarriage
4. Menopause Symptoms May Come Back After Stopping Menopausal Hormone Therapy
5. After the yeast is gone bacteria continue to develop flavor of sparkling wine
6. Researchers Find Drug May Give Some Cardiac Protection 24 Hours After Heart Attack
7. Teens unaware of sexually transmitted diseases until they catch one, Carnegie Mellon study finds
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Bone Density Recovers After Teens Stop Injected Contraceptive

(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
(Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... faced with everyday obstacles in their physical environments and ... with them. Navigating these obstacles can involve highly complex ... work, researchers have employed an ingenious obstacle-based system for ... in the fruit fly Drosophila. , The findings ...
... tailored therapiesContinuing its strong support for studies on ... Institutes of Health anticipates spending more than $150 ... Research Network (PGRN). The research of this nationwide ... drug prescriptions to people's unique genetic make-ups. ...
... have found a family of proteins that enhances the sensitivity ... growth and cancer. Their discovery could lead to a completely ... new drugs to stop uncontrolled growth in a wide variety ... Oxford, funded in part by the Biotechnology and Biological Sciences ...
Cached Biology News:Gap-climbing fruit flies reveal components of goal-driven behaviors 2NIH renews network focused on how genes influence drug responses 2NIH renews network focused on how genes influence drug responses 3NIH renews network focused on how genes influence drug responses 4Fruit fly studies open new window on cancer research 2
(Date:8/31/2015)... , Aug. 31, 2015  RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... announced that the 30-day review period following the ... for ocular indications with the U.S. Food and ... is now active. Logo -  ...
(Date:8/31/2015)... 31, 2015 FLX Bio, Inc., a biopharmaceutical ... cancer immunotherapies, announced today that it has appointed ... and William Ho , M.D., Ph.D., as Chief ... management team led by veterans of Flexus Biosciences, Inc., ... Scientific Officer; Jay Powers , Ph.D., Vice President, ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... as a high priority in the drug development approval process. Thus, innovator companies ... This year, Regis Technologies, Inc., a Chicago-based CMO, has been hosting multiple educational ...
(Date:8/31/2015)... ... ... Proove Biosciences, Inc. is a finalist for the Outstanding Tech Company category of ... its 22nd year, this premier awards event celebrates the best in Orange County’s technology ... world. The OC Tech Alliance will announce all winners at a gala dinner on ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4
... ground-breaking treatment option for victims of whiplash associated disorders (WAD). ... Z Therapy is the first and only rehabilitation specialist in North ... neck pain. , ... Dallas, TX (PRWEB) April 21, ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), a ... to release its financial results for the first quarter ... before the opening of the financial markets.NxStage will also ... on Friday, May 8, 2009 to discuss its first ...
... LLC announced today that it has issued an Executive ... 56-page report can be found at www.crystalra.com ... is a closely held pharmaceutical company focused exclusively on ... a technology spinout from Bayer HealthCare LLC, ACT Biotech ...
Cached Biology Technology:Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers 2NxStage to Report First Quarter 2009 Financial Results 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 3
... Peptide sequences: Two separate vials ... to the same sequence used as ... (Catalog No. 160890) ... Cayman's guanylate cyclase polyclonal antiserum (Catalog ...
... 3B8A10. Immunogen: Recombinant ... C-terminal region of human ... for the human ubiquilin ... (positive control: 293 cells). ...
... PinPoint™ Vector Sequencing Primer is designed for ... Vectors (Cat.# V2031, V2051, V2061). The primer ... at nucleotides 325343, approximately 4050 base pairs ... can be used to determine if an ...
... The versatile Zymo-Spin I-96 Plate can be ... manifolds for the large-scale (i.e., 96-well) purification ... polypropylene construction and unique silica-based matrix make ... g DNA or RNA in = 10 ...
Biology Products: